| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04558892 Details | 2023-01-30 Interventional | 2/3 | [1 Refs] | 65 | Enoxaparin Nephrosis Nephrotic Syndr… Syndrome Thromboembolism Venous Thromboe… | The primary objectives were achieved. - | ||
| NCT04225676 Details | 2023-01-30 Interventional | 2 | 5 | Tisagenlecleuce… Leukemia Leukemia, Lymph… Precursor Cell … Acute Lymphobla… | Terminated due to slow enrollment - | |||
| NCT04035668 2018-004387-54 Details | 2023-01-30 Interventional | 2 | 73 | Remibrutinib Sjogren's Syndr… Syndrome Sjögren Syndro… | Sponsor's decision - | |||
| NCT03810313 2018-001788-21 Details | 2023-01-30 Interventional | 3 | 493 | Aflibercept Macular Edema Retinal Vein Oc… Vision Disorder… Vision, Low Central Retinal… | Study was terminated by sponsor due to increased incidences of adverse events of special
interest (intraocular inflammation including retinal vasculitis, and retinal vascular
occlusion), in patients dosed every 4 weeks beyond 3 initial doses. - | |||
| NCT03802630 2018-001842-33 Details | 2023-01-30 Interventional | 3 | 450 | Aflibercept Macular Edema Retinal Vein Oc… Vision Disorder… Vision, Low Branch Retinal … | Study was terminated by sponsor due to increased incidences of AEs of special interest
(intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in
patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses - | |||
| NCT05408026 Details | 2023-01-27 Interventional | 1/2 | 0 | Bortezomib Daratumumab Dexamethasone Pomalidomide Multiple Myelom… Neoplasms, Plas… Relapsed or Ref… | Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest. - | |||
| NCT04964050 Details | 2023-01-27 Interventional | 1 | 0 | Captopril, hydr… Healthy Volunte… | Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt
EDA (Egyptian drug authority). No subjects were enrolled. - | |||
| NCT04878315 Details | 2023-01-27 Interventional | 1 | 0 | Captopril Healthy Volunte… | Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt
EDA (Egyptian drug authority). No subjects were enrolled. - | |||
| NCT02077959 Details | 2023-01-27 Interventional | 1 | 20 | Lenalidomide Pidilizumab Multiple Myelom… Neoplasms, Plas… | Pharmaceutical Companies decision - | |||
| NCT05060276 Details | 2023-01-26 Interventional | 1 | 0 | Immunoconjugate… Neoplasms Refractory Canc… Relapsed Solid … Solid Tumor, Ad… | Protocol changed to Phase 2 - | |||
| NCT03982173 2018-003115-21 Details | 2023-01-26 Interventional | 2 | 0 | Durvalumab Tremelimumab Adenocarcinoma Triple Negative… Esophageal Aden… Metastatic Colo… Prostate Adenoc… Stomach Adenoca… Triple Negative… | Similar clinical trials showed not very encouraging results, which made us decide, after
several modifications to the protocol and numerous difficulties encountered, to abandon the
trial. - | |||
| NCT03301415 Details | 2023-01-26 Interventional | 2 | 7 | Valganciclovir Cytomegalovirus… Infections Congenital Cyto… | Safety signal The trial was stopped early due to low accrual with only 7 participants enrolled. | |||
| NCT02389543 Details | 2023-01-26 Interventional | 1/2 | 0 | Dexamethasone Lenalidomide Multiple Myelom… Neoplasms, Plas… | Terminated this trial and added a Lenalidomide arm to KCP-330-017 - | |||
| NCT04757857 Details | 2023-01-25 Interventional | 4 | 660 | Rivaroxaban COVID-19 | Sustained reduction in the number of new COVID-19 cases as well as lower than expected event
rates - | |||
| NCT02658812 Details | 2023-01-25 Interventional | 2 | 11 | Talimogene lahe… Breast Neoplasm… Carcinoma Inflammatory Br… Recurrence Malignant Chest… Recurrent Breas… Recurrent Infla… Stage IV Breast… Stage IV Inflam… | Per PI - | |||
| NCT00573378 Details | 2023-01-25 Interventional | 2 | 12 | Peginterferon a… Leukemia Leukemia, Myelo… Leukemia, Myelo… Chronic Myeloid… | - - | |||
| NCT04794088 Details | 2023-01-23 Interventional | 2 | 67 | Imatinib Mesyla… Acute Lung Inju… COVID-19 Pulmonary Edema Respiratory Dis… Respiratory Dis… Syndrome ARDS Acute Respirato… Covid19 Endothelial Dys… | Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on
blinded study data of 66 patients was furthermore favorable, indicating sufficient power to
detect a difference in primary endpoint between groups. - | |||
| NCT01028716 Details | 2023-01-23 Interventional | 2 | 46 | Cyclophosphamid… Fludarabine Fludarabine pho… Lenograstim Mycophenolic Ac… Tacrolimus Burkitt Lymphom… Hematologic Neo… Leukemia Leukemia, Biphe… Leukemia, Eryth… Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, Large… Lymphoma, Mantl… Multiple Myelom… Myelodysplastic… Neoplasms, Plas… Pathologic Comp… Precursor Cell … Preleukemia Recurrence Syndrome Acute Biphenoty… Acute Erythroid… Acute Leukemia … Acute Lymphobla… Acute Myeloid L… Acute Myeloid L… Acute Myeloid L… Acute Myeloid L… Acute Myeloid L… Acute Myeloid L… Acute Undiffere… Adult Acute Lym… B Acute Lymphob… Blasts Under 5 … Childhood Acute… DS Stage II Pla… DS Stage III Pl… Hematopoietic C… Myelodysplastic… Ph+ ALL Recurrent Anapl… Recurrent Folli… Recurrent Hodgk… Recurrent Mantl… Recurrent Margi… Recurrent Plasm… Refractory Plas… Secondary Acute… T Lymphoblastic… | The study experienced lower accrual rates after the onset of COVID. Upon review of the
collected data it was deemed that an adequate amount of subjects has been enrolled to date to
assess study aims. - | |||
| NCT05251376 Details | 2023-01-19 Interventional | 1 | 0 | Methadone Morphine Opioid-Related … Substance-Relat… Opioid Use Diso… | Sponsor decision. - | |||
| NCT04530747 Details | 2023-01-19 Interventional | 1/2 | 16 | Metformin Apnea Sleep Apnea Syn… Sleep Apnea, Ob… | Recall of positive airway pressure (PAP) device. Early termination due to PAP recall. |